Analysts See $-0.20 EPS for Conformis, Inc. (CFMS)

October 14, 2018 - By whatsonthorold

Conformis, Inc. (NASDAQ:CFMS) Logo

Analysts expect Conformis, Inc. (NASDAQ:CFMS) to report $-0.20 EPS on November, 7.They anticipate $0.09 EPS change or 31.03 % from last quarter’s $-0.29 EPS. After having $-0.24 EPS previously, Conformis, Inc.’s analysts see -16.67 % EPS growth. The stock increased 2.22% or $0.02 during the last trading session, reaching $0.92. About 97,905 shares traded. Conformis, Inc. (NASDAQ:CFMS) has declined 70.91% since October 14, 2017 and is downtrending. It has underperformed by 86.53% the S&P500.

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants. The company has market cap of $58.12 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It currently has negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

Another recent and important Conformis, Inc. (NASDAQ:CFMS) news was published by Globenewswire.com which published an article titled: “Conformis Announces Settlement of Patent Dispute with Smith & Nephew” on September 17, 2018.

Conformis, Inc. (NASDAQ:CFMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>